Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial

Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial

Abstract Background Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection with a hospital mortality in excess of 40%. Along with insufficient and delayed empirical antimicrobial therapy, inappropriate antimicrobial exposure has been identified to negative...

Full description

Bibliographic Details
Main Authors: Stefan Hagel, Sandra Fiedler, Andreas Hohn, Alexander Brinkmann, Otto R. Frey, Heike Hoyer, Peter Schlattmann, Michael Kiehntopf, Jason A. Roberts, Mathias W. Pletz, on behalf of the TARGET Study Group
Format: Article
Language:English
Published: BMC 2019-06-01
Series:Trials
Subjects:
Sepsis
Therapeutic drug monitoring (TDM)
Piperacillin
Pharmacokinetics
Pharmacodynamics
Continuous infusion
Online Access:http://link.springer.com/article/10.1186/s13063-019-3437-x

Internet

http://link.springer.com/article/10.1186/s13063-019-3437-x

Similar Items